8-Day Rally Sends Solventum Stock Up 13%
Solventum (SOLV) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 13% return. The company has gained about $1.7 Bil in value over the last 8 days, with its current market capitalization at about $15 Bil. The stock remains 26.2% above its value at the end of 2024. This compares with year-to-date returns of 14% for the S&P 500.
Solventum’s recent streak was fueled by robust Q3 earnings, surpassing estimates, and boosted by a strategic acquisition of wound care innovator Acera Surgical for up to $850M. Complementing this growth, a new $1B share repurchase program signals strong capital allocation and confidence in future performance.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.For quick background, SOLV provides innovative healthcare solutions by developing, manufacturing, and commercializing products that address critical customer and patient needs.
Comparing SOLV Stock Returns With The S&P 500
- CSCO Stock: Two Signals Pointing The Same Way
- Decoding AVGO Stock’s Premium Valuation
- What Could Push NVDA Stock Higher From Here?
- Cash Machine Trading Cheap – Inspire Medical Systems Stock Set to Run?
- Five-Year Tally: AT&T Stock Delivers $58 Bil Gain
- Years of Rewards: $43 Bil From Caterpillar Stock
The following table summarizes the return for SOLV stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SOLV | S&P 500 |
|---|---|---|
| 1D | 0.6% | 1.5% |
| 8D (Current Streak) | 12.9% | -2.1% |
| 1M (21D) | 16.7% | -1.3% |
| 3M (63D) | 14.3% | 3.7% |
| YTD 2025 | 26.2% | 14.0% |
| 2024 | 23.3% | |
| 2023 | 24.2% | |
| 2022 | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 48 S&P constituents with 3 days or more of consecutive gains and 9 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 34 | 4 |
| 4D | 6 | 3 |
| 5D | 5 | 0 |
| 6D | 1 | 2 |
| 7D or more | 2 | 0 |
| Total >=3 D | 48 | 9 |
Key Financials for Solventum (SOLV)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $8.2 Bil | $8.3 Bil |
| Operating Income | $1.7 Bil | $1.0 Bil |
| Net Income | $1.3 Bil | $479.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $2.2 Bil | $2.1 Bil |
| Operating Income | $214.0 Mil | $172.0 Mil |
| Net Income | $90.0 Mil | $1.3 Bil |
While SOLV stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.